Clinical Trial Update: SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating SHR-1701 in combination with rivoceranib (± SHR-2554) for advanced gastric cancer and gastroesophageal junction adenocarcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Rivoceranib (rivoceranib)
• SHR-1701
• SHR-2554

Snippet

Sponsor: Jingdong Zhang | Conditions: Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: RECRUITING